Matthew Blischak
Directeur Général chez FINCH THERAPEUTICS GROUP, INC.
Fortune : - $ au 31/05/2024
Profil
Matthew P.
Blischak is currently the President, Chief Executive Officer & Secretary at Finch Therapeutics Group, Inc. Prior to his current position, he served as the Vice President-Intellectual Property at Roivant Sciences, Inc. from 2018 to 2023.
Mr. Blischak completed his undergraduate degree at Case Western Reserve University and his graduate degrees at The Johns Hopkins University and American University Washington College of Law.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 15/04/2024 | 0 ( -.--% ) | - $ | 31/05/2024 |
Postes actifs de Matthew Blischak
| Sociétés | Poste | Début |
|---|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Directeur Général | 16/05/2023 |
Anciens postes connus de Matthew Blischak
| Sociétés | Poste | Fin |
|---|---|---|
Roivant Sciences, Inc.
 Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/04/2023 |
Formation de Matthew Blischak
| Case Western Reserve University | Undergraduate Degree |
| American University Washington College of Law | Graduate Degree |
| The Johns Hopkins University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| FINCH THERAPEUTICS GROUP, INC. | Health Services |
| Entreprise privées | 1 |
|---|---|
Roivant Sciences, Inc.
Roivant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY. | Health Technology |
